Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Current Leases (2019 - 2022)

Moleculin Biotech (MBRX) has 4 years of Current Leases data on record, last reported at $116000.0 in Q4 2022.

  • For Q4 2022, Current Leases rose 20.83% year-over-year to $116000.0; the TTM value through Dec 2022 reached $116000.0, up 20.83%, while the annual FY2022 figure was $116000.0, 20.83% up from the prior year.
  • Current Leases reached $116000.0 in Q4 2022 per MBRX's latest filing, up from $112000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $122000.0 in Q1 2021 and bottomed at $77000.0 in Q1 2022.
  • Average Current Leases over 4 years is $106222.2, with a median of $112000.0 recorded in 2022.
  • The widest YoY moves for Current Leases: up 20.83% in 2022, down 36.89% in 2022.
  • A 4-year view of Current Leases shows it stood at $103000.0 in 2019, then rose by 14.56% to $118000.0 in 2020, then fell by 18.64% to $96000.0 in 2021, then rose by 20.83% to $116000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Current Leases were $116000.0 in Q4 2022, $112000.0 in Q3 2022, and $98000.0 in Q2 2022.